{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:27:54Z","timestamp":1779362874049,"version":"3.51.4"},"reference-count":23,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T00:00:00Z","timestamp":1304380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background: <\/jats:bold> Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used <jats:sup>18<\/jats:sup>F\u20102\u2010fluoro\u20102\u2010deoxyglucose (<jats:sup>18<\/jats:sup>F\u2010FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC.<\/jats:p><jats:p><jats:bold>Materials and methods: <\/jats:bold> A total of 29 patients with HCC were included. Baseline <jats:sup>18<\/jats:sup>F\u2010FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400\u2003mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0\u201312.0] and 3.8 months (95% CI: 1.4\u20136.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, \u03b1\u2010fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (<jats:italic>P<\/jats:italic>=0.030, <jats:italic>P<\/jats:italic>=0.024, <jats:italic>P<\/jats:italic>=0.020 and <jats:italic>P<\/jats:italic>=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (<jats:italic>P<\/jats:italic>=0.003 and <jats:italic>P<\/jats:italic>=0.026 respectively). When the patients were divided into two groups: low SUVmax (<jats:italic>n<\/jats:italic>=10; &lt;5.00) and high SUVmax (<jats:italic>n<\/jats:italic>=19;\u22655.00), the low SUV group showed significantly longer OS and PFS (<jats:italic>P<\/jats:italic>=0.023 and <jats:italic>P<\/jats:italic>=0.042 respectively).<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold> Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2011.02541.x","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T02:03:34Z","timestamp":1304474614000},"page":"1144-1149","source":"Crossref","is-referenced-by-count":54,"title":["Prognostic value of 18F\u2010FDG PET for hepatocellular carcinoma patients treated with sorafenib"],"prefix":"10.1111","volume":"31","author":[{"given":"Jae Hoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang\u2010Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Jung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Doo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,3]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20933"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14964-1"},{"key":"e_1_2_7_6_2","first-page":"429","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma","volume":"37","author":"Llovet JM","year":"2003","journal-title":"chemoembolization improves survival"},{"key":"e_1_2_7_7_2","first-page":"1535","article-title":"Systematic review","volume":"23","author":"Lopez PM","year":"2006","journal-title":"evidence-based management of hepatocellular carcinoma \u2013 an updated analysis of randomized controlled trials"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0393-4"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_7_11_2","first-page":"25","article-title":"Efficacy and safety of sorafenib in patients in the Asia\u2013Pacific region with advanced hepatocellular carcinoma","volume":"10","author":"Cheng AL","year":"2009","journal-title":"a phase III randomised, double-blind, placebo-controlled trial"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1357"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03888.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.060574"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1284-9"},{"key":"e_1_2_7_16_2","first-page":"41","article-title":"Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma","volume":"7","author":"Zhang Z","year":"2009","journal-title":"evidence from an in vitro study"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3441"},{"key":"e_1_2_7_18_2","article-title":"Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. AASLD 59th Annual Meeting","author":"Llovet JM","year":"2008","journal-title":"Hepatology"},{"key":"e_1_2_7_19_2","first-page":"3027","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma","volume":"27","author":"Zhu AX","year":"2009","journal-title":"a phase II study"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2480"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25019"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5655"},{"key":"e_1_2_7_23_2","first-page":"2472","article-title":"To predict progression\u2010free survival and overall survival in metastatic renal cancer treated with sorafenib","volume":"42","author":"Lamuraglia M","year":"2006","journal-title":"pilot study using dynamic contrast-enhanced Doppler ultrasound"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1454-2"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2011.02541.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2011.02541.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:50:21Z","timestamp":1695495021000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2011.02541.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,3]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1478-3231.2011.02541.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02541.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,3]]}}}